Hale Yarmohammadi1, Charlotte Cunningham-Rundles2. 1. Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: hale.yar@mssm.edu. 2. Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
BACKGROUND: Idiopathic CD4 lymphocytopenia (ICL) is a rare condition characterized by an unexplained deficit of circulating CD4 T cells leading to increased risk of serious opportunistic infections. The pathogenesis, etiology, clinical presentation, and best treatment options remain unclear. OBJECTIVE: To describe the clinical presentation, treatment strategies, and outcome of patients with ICL seen in a single referral center. METHODS: In a retrospective study, from January 1993 to January 2014, the demographic characteristics, clinical presentation, and treatments of patients diagnosed with ICL were reviewed. RESULTS: Twenty-four patients (14 female [58%] and 10 male [42%]) were evaluated. The mean age was 45 ± 17.6 years (range 7-76 years). Mean CD4 and CD8 T-cell counts at the time of diagnosis were 119 ± 84/mm3 (range 4-294/mm3) and 219 ± 258/mm3 (range 7-630/mm3), respectively. Seventeen patients (71%) had opportunistic infections, 4 (17%) had malignancies, and 3 (13%) had unexplained demyelinating disease and neurologic problems. Most patients had normal levels of immunoglobulins. Thirteen patients had abnormally low to absent response to phytohemagglutinin, concanavalin A, and antigens (candida and tetanus). Three patients had resolution of warts and 1 had mycobacterial lung infection on interleukin-2 with increases in CD4 count. The 11 patients on trimethoprim and sulfamethoxazole had no further hospital admissions for infections. CONCLUSION: The pathogenesis of ICL remains unclear. Although only some patients are healthy, most patients present with opportunistic infections. There is no known standard treatment aside from prophylactic antibiotics.
BACKGROUND:Idiopathic CD4 lymphocytopenia (ICL) is a rare condition characterized by an unexplained deficit of circulating CD4 T cells leading to increased risk of serious opportunistic infections. The pathogenesis, etiology, clinical presentation, and best treatment options remain unclear. OBJECTIVE: To describe the clinical presentation, treatment strategies, and outcome of patients with ICL seen in a single referral center. METHODS: In a retrospective study, from January 1993 to January 2014, the demographic characteristics, clinical presentation, and treatments of patients diagnosed with ICL were reviewed. RESULTS: Twenty-four patients (14 female [58%] and 10 male [42%]) were evaluated. The mean age was 45 ± 17.6 years (range 7-76 years). Mean CD4 and CD8 T-cell counts at the time of diagnosis were 119 ± 84/mm3 (range 4-294/mm3) and 219 ± 258/mm3 (range 7-630/mm3), respectively. Seventeen patients (71%) had opportunistic infections, 4 (17%) had malignancies, and 3 (13%) had unexplained demyelinating disease and neurologic problems. Most patients had normal levels of immunoglobulins. Thirteen patients had abnormally low to absent response to phytohemagglutinin, concanavalin A, and antigens (candida and tetanus). Three patients had resolution of warts and 1 had mycobacterial lung infection on interleukin-2 with increases in CD4 count. The 11 patients on trimethoprim and sulfamethoxazole had no further hospital admissions for infections. CONCLUSION: The pathogenesis of ICL remains unclear. Although only some patients are healthy, most patients present with opportunistic infections. There is no known standard treatment aside from prophylactic antibiotics.
Authors: T Iwase; K Ojika; E Katada; S Mitake; H Nakazawa; N Matsukawa; Y Otsuka; Y Tsugu; H Kanai; K Nakajima Journal: J Neurol Neurosurg Psychiatry Date: 1998-06 Impact factor: 10.154
Authors: Ainhoa Perez-Diez; Chun-Shu Wong; Xiangdong Liu; Harry Mystakelis; Jian Song; Yong Lu; Virginia Sheikh; Jeffrey S Bourgeois; Andrea Lisco; Elizabeth Laidlaw; Cornelia Cudrici; Chengsong Zhu; Quan-Zhen Li; Alexandra F Freeman; Peter R Williamson; Megan Anderson; Gregg Roby; John S Tsang; Richard Siegel; Irini Sereti Journal: J Clin Invest Date: 2020-10-01 Impact factor: 14.808
Authors: Aminaa E Siddiqi; Anne Y Liu; Gregory W Charville; Christian A Kunder; Gulbu Uzel; Amir A Sadighi Akha; Jean Oak; Beth Martin; Joshua Sacha; David B Lewis; Yael Gernez Journal: J Clin Immunol Date: 2020-01-18 Impact factor: 8.317
Authors: Christina S Thornton; Oscar Larios; Jennifer Grossman; Thomas P Griener; Steven Vaughan Journal: BMC Infect Dis Date: 2019-10-17 Impact factor: 3.090